These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32757807)

  • 1. PESM: A novel approach of tumor purity estimation based on sample specific methylation sites.
    Pang S; Wang L; Wang S; Zhang Y; Wang X
    J Bioinform Comput Biol; 2020 Oct; 18(5):2050027. PubMed ID: 32757807
    [No Abstract]   [Full Text] [Related]  

  • 2. PEIS: a novel approach of tumor purity estimation by identifying information sites through integrating signal based on DNA methylation data.
    Wang S; Wang L; Zhang Y; Pang S; Wang X
    BMC Bioinformatics; 2019 Dec; 20(Suppl 22):714. PubMed ID: 31888435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An effective seven-CpG-based signature to predict survival in renal clear cell carcinoma by integrating DNA methylation and gene expression.
    Xu L; He J; Cai Q; Li M; Pu X; Guo Y
    Life Sci; 2020 Feb; 243():117289. PubMed ID: 31926254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and prognostic biomarkers of common urological cancers based on aberrant DNA methylation.
    Peng D; Ge G; Xu Z; Ma Q; Shi Y; Zhou Y; Gong Y; Xiong G; Zhang C; He S; He Z; Li X; Ci W; Zhou L
    Epigenomics; 2018 Sep; 10(9):1189-1199. PubMed ID: 30182734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive characterization of immune- and inflammation-associated biomarkers based on multi-omics integration in kidney renal clear cell carcinoma.
    Zhao E; Li L; Zhang W; Wang W; Chan Y; You B; Li X
    J Transl Med; 2019 May; 17(1):177. PubMed ID: 31133033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of methylation-driven genes related to prognosis in clear-cell renal cell carcinoma.
    Wang J; Zhang Q; Zhu Q; Liu C; Nan X; Wang F; Fang L; Liu J; Xie C; Fu S; Song B
    J Cell Physiol; 2020 Feb; 235(2):1296-1308. PubMed ID: 31273792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying CpG sites with different differential methylation frequencies in colorectal cancer tissues based on individualized differential methylation analysis.
    Yan H; He J; Guan Q; Cai H; Zhang L; Zheng W; Qi L; Zhang S; Liu H; Li H; Zhao W; Yang S; Guo Z
    Oncotarget; 2017 Jul; 8(29):47356-47364. PubMed ID: 28537885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
    Mendoza-Pérez J; Gu J; Herrera LA; Tannir NM; Zhang S; Matin S; Karam JA; Wood CG; Wu X
    Cancer; 2017 Sep; 123(18):3617-3627. PubMed ID: 28543182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LogLoss-BERAF: An ensemble-based machine learning model for constructing highly accurate diagnostic sets of methylation sites accounting for heterogeneity in prostate cancer.
    Babalyan K; Sultanov R; Generozov E; Sharova E; Kostryukova E; Larin A; Kanygina A; Govorun V; Arapidi G
    PLoS One; 2018; 13(11):e0204371. PubMed ID: 30388122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value and potential subtypes of immune activity scores in three major urological cancers.
    Shi B; Qi J
    J Cell Physiol; 2021 Apr; 236(4):2620-2630. PubMed ID: 32853461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer.
    Li H; Kim C; Liu W; Zhu J; Chin K; Rodriguez-Canales J; Rodgers GP
    Int J Cancer; 2020 Mar; 146(5):1346-1358. PubMed ID: 31241767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized analysis reveals CpG sites with methylation aberrations in almost all lung adenocarcinoma tissues.
    Yan H; Guan Q; He J; Lin Y; Zhang J; Li H; Liu H; Gu Y; Guo Z; He F
    J Transl Med; 2017 Feb; 15(1):26. PubMed ID: 28178989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor purity quantification by clonal DNA methylation signatures.
    Benelli M; Romagnoli D; Demichelis F
    Bioinformatics; 2018 May; 34(10):1642-1649. PubMed ID: 29325057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accounting for differential variability in detecting differentially methylated regions.
    Wang Y; Teschendorff AE; Widschwendter M; Wang S
    Brief Bioinform; 2019 Jan; 20(1):47-57. PubMed ID: 29912290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Universal informative CpG sites for inferring tumor purity from DNA methylation microarray data.
    Dou H; Fang Y; Zheng X
    J Bioinform Comput Biol; 2018 Jun; 16(3):1750030. PubMed ID: 29347875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Gene Signature of Survival Prediction for Kidney Renal Cell Carcinoma by Multi-Omic Data Analysis.
    Hu F; Zeng W; Liu X
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Methylation profile of group of miRNA genes in clear cell renal cell carcinoma; involvement in cancer progression].
    Beresneva EV; Rykov SV; Hodyrev DS; Pronina IV; Ermilova VD; Kazubskaia TP; Braga EA; Loginov VI
    Genetika; 2013 Mar; 49(3):366-75. PubMed ID: 23755536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma.
    Yang M; Hlady RA; Zhou D; Ho TH; Robertson KD
    Cancer Med; 2019 Sep; 8(12):5760-5768. PubMed ID: 31361072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter CpG island methylation in ion transport mechanisms and associated dietary intakes jointly influence the risk of clear-cell renal cell cancer.
    Deckers IA; van Engeland M; van den Brandt PA; Van Neste L; Soetekouw PM; Aarts MJ; Baldewijns MM; Keszei AP; Schouten LJ
    Int J Epidemiol; 2017 Apr; 46(2):622-631. PubMed ID: 27789672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression.
    Peters I; Eggers H; Atschekzei F; Hennenlotter J; Waalkes S; Tränkenschuh W; Grosshennig A; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
    BJU Int; 2012 Jul; 110(2 Pt 2):E144-52. PubMed ID: 22289415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.